Single User License
INR 169825
Site License
INR 339650
Corporate User License
INR 509475

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Neuropathic Pain-Pipeline Review, H1 2015

Neuropathic Pain-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Neuropathic Pain-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Neuropathic Pain-Pipeline Review, H1 2015', provides an overview of the Neuropathic Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuropathic Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Neuropathic Pain

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Neuropathic Pain and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Neuropathic Pain pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Neuropathic Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 8

Neuropathic Pain Overview 9

Therapeutics Development 10

Neuropathic Pain-Therapeutics under Development by Companies 12

Neuropathic Pain-Therapeutics under Investigation by Universities/Institutes 24

Neuropathic Pain-Pipeline Products Glance 27

Neuropathic Pain-Products under Development by Companies 31

Neuropathic Pain-Products under Investigation by Universities/Institutes 46

Neuropathic Pain-Companies Involved in Therapeutics Development 49

Neuropathic Pain-Therapeutics Assessment 173

Drug Profiles 191

Neuropathic Pain-Recent Pipeline Updates 485

Neuropathic Pain-Dormant Projects 545

Neuropathic Pain-Discontinued Products 563

Neuropathic Pain-Product Development Milestones 571

Appendix 578

List of Tables

Number of Products under Development for Neuropathic Pain, H1 2015 37

Number of Products under Development for Neuropathic Pain-Comparative Analysis, H1 2015 38

Number of Products under Development by Companies, H1 2015 40

Number of Products under Development by Companies, H1 2015 (Contd..1) 41

Number of Products under Development by Companies, H1 2015 (Contd..2) 42

Number of Products under Development by Companies, H1 2015 (Contd..3) 43

Number of Products under Development by Companies, H1 2015 (Contd..4) 44

Number of Products under Development by Companies, H1 2015 (Contd..5) 45

Number of Products under Development by Companies, H1 2015 (Contd..6) 46

Number of Products under Development by Companies, H1 2015 (Contd..7) 47

Number of Products under Development by Companies, H1 2015 (Contd..8) 48

Number of Products under Development by Companies, H1 2015 (Contd..9) 49

Number of Products under Development by Companies, H1 2015 (Contd..10) 50

Number of Products under Investigation by Universities/Institutes, H1 2015 52

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 53

Comparative Analysis by Late Stage Development, H1 2015 54

Comparative Analysis by Clinical Stage Development, H1 2015 55

Comparative Analysis by Early Stage Development, H1 2015 56

Comparative Analysis by Unknown Stage Development, H1 2015 57

Products under Development by Companies, H1 2015 58

Products under Development by Companies, H1 2015 (Contd..1) 59

Products under Development by Companies, H1 2015 (Contd..2) 60

Products under Development by Companies, H1 2015 (Contd..3) 61

Products under Development by Companies, H1 2015 (Contd..4) 62

Products under Development by Companies, H1 2015 (Contd..5) 63

Products under Development by Companies, H1 2015 (Contd..6) 64

Products under Development by Companies, H1 2015 (Contd..7) 65

Products under Development by Companies, H1 2015 (Contd..8) 66

Products under Development by Companies, H1 2015 (Contd..9) 67

Products under Development by Companies, H1 2015 (Contd..10) 68

Products under Development by Companies, H1 2015 (Contd..11) 69

Products under Development by Companies, H1 2015 (Contd..12) 70

Products under Development by Companies, H1 2015 (Contd..13) 71

Products under Development by Companies, H1 2015 (Contd..14) 72

Products under Investigation by Universities/Institutes, H1 2015 73

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 74

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 75

Neuropathic Pain-Pipeline by AbbVie Inc., H1 2015 76

Neuropathic Pain-Pipeline by Advinus Therapeutics Ltd., H1 2015 77

Neuropathic Pain-Pipeline by Adynxx, Inc., H1 2015 78

Neuropathic Pain-Pipeline by Aestus Therapeutics, Inc., H1 2015 79

Neuropathic Pain-Pipeline by Affectis Pharmaceuticals AG, H1 2015 80

Neuropathic Pain-Pipeline by Allergan, Inc., H1 2015 81

Neuropathic Pain-Pipeline by Amura Holdings Limited, H1 2015 82

Neuropathic Pain-Pipeline by AnaBios Corporation, H1 2015 83

Neuropathic Pain-Pipeline by Anavex Life Sciences Corp., H1 2015 84

Neuropathic Pain-Pipeline by AngioChem Inc., H1 2015 85

Neuropathic Pain-Pipeline by Asahi Kasei Pharma Corp., H1 2015 86

Neuropathic Pain-Pipeline by Astellas Pharma Inc., H1 2015 87

Neuropathic Pain-Pipeline by AstraZeneca Plc, H1 2015 88

Neuropathic Pain-Pipeline by BBB Therapeutics B.V., H1 2015 89

Neuropathic Pain-Pipeline by BCN Peptides, S.A., H1 2015 90

Neuropathic Pain-Pipeline by Benitec Biopharma Limited, H1 2015 91

Neuropathic Pain-Pipeline by BioDelivery Sciences International, Inc., H1 2015 92

Neuropathic Pain-Pipeline by Biogen, Inc., H1 2015 93

Neuropathic Pain-Pipeline by BioLineRx, Ltd., H1 2015 94

Neuropathic Pain-Pipeline by Biomar Microbial Technologies, H1 2015 95

Neuropathic Pain-Pipeline by Bionomics Limited, H1 2015 96

Neuropathic Pain-Pipeline by Boehringer Ingelheim GmbH, H1 2015 97

Neuropathic Pain-Pipeline by Bristol-Myers Squibb Company, H1 2015 98

Neuropathic Pain-Pipeline by Can-Fite BioPharma Ltd., H1 2015 99

Neuropathic Pain-Pipeline by Cara Therapeutics, Inc., H1 2015 100

Neuropathic Pain-Pipeline by Cavion LLC, H1 2015 101

Neuropathic Pain-Pipeline by Cerecor Inc., H1 2015 102

Neuropathic Pain-Pipeline by CLL Pharma, H1 2015 103

Neuropathic Pain-Pipeline by Colby Pharmaceutical Company, H1 2015 104

Neuropathic Pain-Pipeline by Concert Pharmaceuticals, Inc., H1 2015 105

Neuropathic Pain-Pipeline by Convergence Pharmaceuticals Ltd., H1 2015 106

Neuropathic Pain-Pipeline by Creabilis SA, H1 2015 107

Neuropathic Pain-Pipeline by Crinetics Pharmaceuticals, Inc., H1 2015 108

Neuropathic Pain-Pipeline by Cytogel Pharma, LLC, H1 2015 109

Neuropathic Pain-Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 110

Neuropathic Pain-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 111

Neuropathic Pain-Pipeline by DermaXon, LLC, H1 2015 112

Neuropathic Pain-Pipeline by Dong-A Socio Group, H1 2015 113

Neuropathic Pain-Pipeline by Eisai Co., Ltd., H1 2015 114

Neuropathic Pain-Pipeline by Eli Lilly and Company, H1 2015 115

Neuropathic Pain-Pipeline by Endece, LLC, H1 2015 116

Neuropathic Pain-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 117

Neuropathic Pain-Pipeline by Evotec AG, H1 2015 118

Neuropathic Pain-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 119

Neuropathic Pain-Pipeline by Genecode AS, H1 2015 120

Neuropathic Pain-Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015 121

Neuropathic Pain-Pipeline by Glialogix, Inc., H1 2015 122

Neuropathic Pain-Pipeline by Grunenthal GmbH, H1 2015 123

Neuropathic Pain-Pipeline by GW Pharmaceuticals Plc, H1 2015 124

Neuropathic Pain-Pipeline by Hydra Biosciences, Inc., H1 2015 125

Neuropathic Pain-Pipeline by Immune Pharmaceuticals Inc., H1 2015 126

Neuropathic Pain-Pipeline by Integral Molecular, Inc., H1 2015 127

Neuropathic Pain-Pipeline by IntelGenx Corp., H1 2015 128

Neuropathic Pain-Pipeline by Intellipharmaceutics International Inc., H1 2015 129

Neuropathic Pain-Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2015 130

Neuropathic Pain-Pipeline by Johnson & Johnson, H1 2015 131

Neuropathic Pain-Pipeline by Kareus Therapeutics, SA, H1 2015 132

Neuropathic Pain-Pipeline by Kineta, Inc., H1 2015 133

Neuropathic Pain-Pipeline by Knopp Biosciences LLC, H1 2015 134

Neuropathic Pain-Pipeline by KunWha Pharmaceutical Co., Ltd., H1 2015 135

Neuropathic Pain-Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2015 136

Neuropathic Pain-Pipeline by LEO Pharma A/S, H1 2015 137

Neuropathic Pain-Pipeline by Lexicon Pharmaceuticals, Inc., H1 2015 138

Neuropathic Pain-Pipeline by Lipopharma Therapeutics SL, H1 2015 139

Neuropathic Pain-Pipeline by Lohocla Research Corporation, H1 2015 140

Neuropathic Pain-Pipeline by Lpath, Inc., H1 2015 141

Neuropathic Pain-Pipeline by Maruho Co., Ltd., H1 2015 142

Neuropathic Pain-Pipeline by Medy-Tox Inc., H1 2015 143

Neuropathic Pain-Pipeline by Merck & Co., Inc., H1 2015 144

Neuropathic Pain-Pipeline by Mertiva AB, H1 2015 145

Neuropathic Pain-Pipeline by Metys Pharmaceuticals AG, H1 2015 146

Neuropathic Pain-Pipeline by Nanomerics Ltd, H1 2015 147

Neuropathic Pain-Pipeline by Nektar Therapeutics, H1 2015 148

Neuropathic Pain-Pipeline by Neurim Pharmaceuticals Ltd, H1 2015 149

Neuropathic Pain-Pipeline by Neurocentrx Pharma Ltd., H1 2015 150

Neuropathic Pain-Pipeline by Neurodyn Inc., H1 2015 151

Neuropathic Pain-Pipeline by NeurOp, Inc, H1 2015 152

Neuropathic Pain-Pipeline by Newron Pharmaceuticals S.p.A., H1 2015 153

Neuropathic Pain-Pipeline by Nippon Chemiphar Co., Ltd., H1 2015 154

Neuropathic Pain-Pipeline by NsGene A/S, H1 2015 155

Neuropathic Pain-Pipeline by Nuvo Research Inc., H1 2015 156

Neuropathic Pain-Pipeline by Orion Oyj, H1 2015 157

Neuropathic Pain-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 158

Neuropathic Pain-Pipeline by Pfizer Inc., H1 2015 159

Neuropathic Pain-Pipeline by Pharmaleads , H1 2015 160

Neuropathic Pain-Pipeline by PharmEste, H1 2015 161

Neuropathic Pain-Pipeline by Phosphagenics Limited, H1 2015 162

Neuropathic Pain-Pipeline by Protagonist Therapeutics Inc., H1 2015 163

Neuropathic Pain-Pipeline by Purdue Pharma L.P., H1 2015 164

Neuropathic Pain-Pipeline by Quark Pharmaceuticals, Inc., H1 2015 165

Neuropathic Pain-Pipeline by RAPID Pharmaceuticals AG, H1 2015 166

Neuropathic Pain-Pipeline by RaQualia Pharma Inc., H1 2015 167

Neuropathic Pain-Pipeline by Re-Pharm Limited, H1 2015 168

Neuropathic Pain-Pipeline by Recro Pharma, Inc., H1 2015 169

Neuropathic Pain-Pipeline by Relmada Therapeutics, Inc., H1 2015 170

Neuropathic Pain-Pipeline by Revance Therapeutics, Inc., H1 2015 171

Neuropathic Pain-Pipeline by Rottapharm SpA, H1 2015 172

Neuropathic Pain-Pipeline by Saniona AB, H1 2015 173

Neuropathic Pain-Pipeline by Scilex Pharmaceuticals, Inc., H1 2015 174

Neuropathic Pain-Pipeline by Shionogi & Co., Ltd., H1 2015 175

Neuropathic Pain-Pipeline by Sigma-Tau S.p.A., H1 2015 176

Neuropathic Pain-Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 177

Neuropathic Pain-Pipeline by Snowdon Inc., H1 2015 178

Neuropathic Pain-Pipeline by Sova Pharmaceuticals, Inc., H1 2015 179

Neuropathic Pain-Pipeline by Sphaera Pharma Pvt. Ltd., H1 2015 180

Neuropathic Pain-Pipeline by Spinifex Pharmaceuticals Pty Limited, H1 2015 181

Neuropathic Pain-Pipeline by Sunovion Pharmaceuticals Inc., H1 2015 182

Neuropathic Pain-Pipeline by Syntrix Biosystems, Inc., H1 2015 183

Neuropathic Pain-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 184

Neuropathic Pain-Pipeline by Targacept, Inc., H1 2015 185

Neuropathic Pain-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 186

Neuropathic Pain-Pipeline by Theravasc, Inc., H1 2015 187

Neuropathic Pain-Pipeline by Toray Industries, Inc., H1 2015 188

Neuropathic Pain-Pipeline by Torrent Pharmaceuticals Limited, H1 2015 189

Neuropathic Pain-Pipeline by Trevena, Inc., H1 2015 190

Neuropathic Pain-Pipeline by Trigemina, Inc., H1 2015 191

Neuropathic Pain-Pipeline by Vernalis Plc, H1 2015 192

Neuropathic Pain-Pipeline by Vichem Chemie Research Ltd., H1 2015 193

Neuropathic Pain-Pipeline by Virobay Inc., H1 2015 194

Neuropathic Pain-Pipeline by VistaGen Therapeutics , Inc., H1 2015 195

Neuropathic Pain-Pipeline by WEX Pharmaceuticals Inc., H1 2015 196

Neuropathic Pain-Pipeline by Winston Pharmaceuticals, Inc., H1 2015 197

Neuropathic Pain-Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 198

Neuropathic Pain-Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 199

Assessment by Monotherapy Products, H1 2015 200

Assessment by Combination Products, H1 2015 201

Number of Products by Stage and Target, H1 2015 203

Number of Products by Stage and Mechanism of Action, H1 2015 209

Number of Products by Stage and Route of Administration, H1 2015 215

Number of Products by Stage and Molecule Type, H1 2015 217

Neuropathic Pain Therapeutics-Recent Pipeline Updates, H1 2015 512

Neuropathic Pain-Dormant Projects, H1 2015 572

Neuropathic Pain-Dormant Projects (Contd..1), H1 2015 573

Neuropathic Pain-Dormant Projects (Contd..2), H1 2015 574

Neuropathic Pain-Dormant Projects (Contd..3), H1 2015 575

Neuropathic Pain-Dormant Projects (Contd..4), H1 2015 576

Neuropathic Pain-Dormant Projects (Contd..5), H1 2015 577

Neuropathic Pain-Dormant Projects (Contd..6), H1 2015 578

Neuropathic Pain-Dormant Projects (Contd..7), H1 2015 579

Neuropathic Pain-Dormant Projects (Contd..8), H1 2015 580

Neuropathic Pain-Dormant Projects (Contd..9), H1 2015 581

Neuropathic Pain-Dormant Projects (Contd..10), H1 2015 582

Neuropathic Pain-Dormant Projects (Contd..11), H1 2015 583

Neuropathic Pain-Dormant Projects (Contd..12), H1 2015 584

Neuropathic Pain-Dormant Projects (Contd..13), H1 2015 585

Neuropathic Pain-Dormant Projects (Contd..14), H1 2015 586

Neuropathic Pain-Dormant Projects (Contd..15), H1 2015 587

Neuropathic Pain-Dormant Projects (Contd..16), H1 2015 588

Neuropathic Pain-Dormant Projects (Contd..17), H1 2015 589

Neuropathic Pain-Discontinued Products, H1 2015 590

Neuropathic Pain-Discontinued Products (Contd..1), H1 2015 591

Neuropathic Pain-Discontinued Products (Contd..2), H1 2015 592

Neuropathic Pain-Discontinued Products (Contd..3), H1 2015 593

Neuropathic Pain-Discontinued Products (Contd..4), H1 2015 594

Neuropathic Pain-Discontinued Products (Contd..5), H1 2015 595

Neuropathic Pain-Discontinued Products (Contd..6), H1 2015 596

Neuropathic Pain-Discontinued Products (Contd..7), H1 2015 597

List of Figures

Number of Products under Development for Neuropathic Pain, H1 2015 37

Number of Products under Development for Neuropathic Pain-Comparative Analysis, H1 2015 38

Number of Products under Development by Companies, H1 2015 39

Number of Products under Investigation by Universities/Institutes, H1 2015 51

Comparative Analysis by Clinical Stage Development, H1 2015 55

Comparative Analysis by Early Stage Products, H1 2015 56

Assessment by Monotherapy Products, H1 2015 200

Assessment by Combination Products, H1 2015 201

Number of Products by Top 10 Targets, H1 2015 202

Number of Products by Stage and Top 10 Targets, H1 2015 202

Number of Products by Top 10 Mechanism of Actions, H1 2015 208

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 208

Number of Products by Top 10 Routes of Administration, H1 2015 214

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 214

Number of Products by Top 10 Molecule Types, H1 2015 216

Number of Products by Stage and Top 10 Molecule Types, H1 2015 216

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Advinus Therapeutics Ltd.

Adynxx, Inc.

Aestus Therapeutics, Inc.

Affectis Pharmaceuticals AG

Allergan, Inc.

Amura Holdings Limited

AnaBios Corporation

Anavex Life Sciences Corp.

AngioChem Inc.

Asahi Kasei Pharma Corp.

Astellas Pharma Inc.

AstraZeneca Plc

BBB Therapeutics B.V.

BCN Peptides, S.A.

Benitec Biopharma Limited

BioDelivery Sciences International, Inc.

Biogen, Inc.

BioLineRx, Ltd.

Biomar Microbial Technologies

Bionomics Limited

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Can-Fite BioPharma Ltd.

Cara Therapeutics, Inc.

Cavion LLC

Cerecor Inc.

CLL Pharma

Colby Pharmaceutical Company

Concert Pharmaceuticals, Inc.

Convergence Pharmaceuticals Ltd.

Creabilis SA

Crinetics Pharmaceuticals, Inc.

Cytogel Pharma, LLC

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

DermaXon, LLC

Dong-A Socio Group

Eisai Co., Ltd.

Eli Lilly and Company

Endece, LLC

Epirus Biopharmaceuticals, Inc.

Evotec AG

F. Hoffmann-La Roche Ltd.

Genecode AS

Glenmark Pharmaceuticals Ltd.

Glialogix, Inc.

Grunenthal GmbH

GW Pharmaceuticals Plc

Hydra Biosciences, Inc.

Immune Pharmaceuticals Inc.

Integral Molecular, Inc.

IntelGenx Corp.

Intellipharmaceutics International Inc.

Jeil Pharmaceutical Co., Ltd.

Johnson & Johnson

Kareus Therapeutics, SA

Kineta, Inc.

Knopp Biosciences LLC

KunWha Pharmaceutical Co., Ltd.

Laboratorios Del Dr. Esteve S.A.

LEO Pharma A/S

Lexicon Pharmaceuticals, Inc.

Lipopharma Therapeutics SL

Lohocla Research Corporation

Lpath, Inc.

Maruho Co., Ltd.

Medy-Tox Inc.

Merck & Co., Inc.

Mertiva AB

Metys Pharmaceuticals AG

Nanomerics Ltd

Nektar Therapeutics

Neurim Pharmaceuticals Ltd

Neurocentrx Pharma Ltd.

Neurodyn Inc.

NeurOp, Inc

Newron Pharmaceuticals S.p.A.

Nippon Chemiphar Co., Ltd.

NsGene A/S

Nuvo Research Inc.

Orion Oyj

Otsuka Holdings Co., Ltd.

Pfizer Inc.

Pharmaleads

PharmEste

Phosphagenics Limited

Protagonist Therapeutics Inc.

Purdue Pharma L.P.

Quark Pharmaceuticals, Inc.

RAPID Pharmaceuticals AG

RaQualia Pharma Inc.

Re-Pharm Limited

Recro Pharma, Inc.

Relmada Therapeutics, Inc.

Revance Therapeutics, Inc.

Rottapharm SpA

Saniona AB

Scilex Pharmaceuticals, Inc.

Shionogi & Co., Ltd.

Sigma-Tau S.p.A.

SK Biopharmaceuticals Co., Ltd.

Snowdon Inc.

Sova Pharmaceuticals, Inc.

Sphaera Pharma Pvt. Ltd.

Spinifex Pharmaceuticals Pty Limited

Sunovion Pharmaceuticals Inc.

Syntrix Biosystems, Inc.

Takeda Pharmaceutical Company Limited

Targacept, Inc.

Teva Pharmaceutical Industries Limited

Theravasc, Inc.

Toray Industries, Inc.

Torrent Pharmaceuticals Limited

Trevena, Inc.

Trigemina, Inc.

Vernalis Plc

Vichem Chemie Research Ltd.

Virobay Inc.

VistaGen Therapeutics , Inc.

WEX Pharmaceuticals Inc.

Winston Pharmaceuticals, Inc.

Yungjin Pharm Ind. Co., Ltd.

Zynerba Pharmaceuticals, Inc.

Neuropathic Pain Therapeutic Products under Development, Key Players in Neuropathic Pain Therapeutics, Neuropathic Pain Pipeline Overview, Neuropathic Pain Pipeline, Neuropathic Pain Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com